Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.

Autor: Tolmeijer SH; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., van Wilpe S; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Geerlings MJ; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., von Rhein D; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Smilde TJ; Department of Medical Oncology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands., Kloots ISH; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Westdorp H; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Coskuntürk M; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, The Netherlands., van Ipenburg JA; Department of Pathology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., van der Heijden AG; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Hofste T; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Weiss MM; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Schalken JA; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Gerritsen WR; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Ligtenberg MJL; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Pathology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Mehra N; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Niven.mehra@radboudumc.nl.

Publikováno v: European urology oncology [Eur Urol Oncol] 2024 Apr; Vol. 7 (2), pp. 282-291. Date of Electronic Publication: 2023 Sep 04.

Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study.

Autor: Pape M; Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.; Amsterdam UMC location University of Amsterdam, Medical Oncology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands., Vissers PAJ; Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.; Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands., Dijksterhuis WPM; Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.; Amsterdam UMC location University of Amsterdam, Medical Oncology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands., Bertwistle D; Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Uxbridge, UK., McDonald L; Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Uxbridge, UK., Mostert B; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Derks S; Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, The Netherlands., Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, the Netherlands., Verhoeven RHA; Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.; Amsterdam UMC location University of Amsterdam, Medical Oncology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands., van Laarhoven HWM; Amsterdam UMC location University of Amsterdam, Medical Oncology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands.; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.

Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Mar 21; Vol. 15, pp. 17588359231162576. Date of Electronic Publication: 2023 Mar 21 (Print Publication: 2023).

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.

Autor: Opdam M; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, Netherlands., Kleijn M; Medical Affairs, Agendia NV, Amsterdam, Netherlands., Glas A; Medical Affairs, Agendia NV, Amsterdam, Netherlands., Mandjes I; Biometrics Department, Netherlands Cancer Institute, Amsterdam, Netherlands., Kleiterp S; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands., Hilbers FS; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands., Kruger DT; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands., Bins AD; Department of Medical Oncology, Amsterdam UMC, Amsterdam, Netherlands., de Jong PC; Department of Medical Oncology, Sint-Antonius Hospital, Nieuwegein, Netherlands., Schiphorst PPJBM; Department of Internal Medicine, Streekziekenhuis Koningin. Beatrix, Winterswijk, Netherlands., van Dalen T; Department of Surgery, Diakonessenhuis, Utrecht, Netherlands., Flameling B; Department of Medical Oncology, OLVG, Amsterdam, Netherlands., Rietbroek RC; Department of Internal Medicine, Red Cross Hospital, Beverwijk, Netherlands., Beeker A; Department of Medical Oncology, Spaarne Gasthuis, Hoofddorp, Netherlands., van den Heiligenberg SM; Department of Medical Oncology, Dijklander Ziekenhuis, Hoorn, Netherlands., Bakker SD; Department of Internal Medicine, Zaans Medisch Centrum, Zaandam, Netherlands., Wymenga ANM; Department of Medical Oncology, Medisch Spectrum Twente, Enschede, Netherlands., Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, the Netherlands., Bijlsma RM; Department of Medical Oncology, UMCU, Utrecht, Netherlands., van Diest PJ; Department of Pathology, UMCU, Utrecht, Netherlands., Vermorken JB; Department of Medical Oncology, University Hospital Antwerp (UZA), Edegem, Belgium.; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., van Tinteren H; Biometrics Department, Netherlands Cancer Institute, Amsterdam, Netherlands.; Trial and Data Center, Princess Maxima Centre for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands., Linn SC; Department of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands. s.linn@nki.nl.; Department of Medical Oncology, UMCU, Utrecht, Netherlands. s.linn@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands. s.linn@nki.nl.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Jul; Vol. 194 (2), pp. 265-278. Date of Electronic Publication: 2022 May 19.

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.

Autor: Boerrigter E; Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands., Benoist GE; Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands., van Oort IM; Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands., Verhaegh GW; Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands., van Hooij O; Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands., Groen L; Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands., Smit F; MDxHealth, Nijmegen, the Netherlands., Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, the Netherlands., de Mol P; Department of Medical Oncology, Gelderse Vallei Hospital, Ede, the Netherlands., Smilde TJ; Department of Medical Oncology, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands., Somford DM; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands., Mehra N; Deparment of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Schalken JA; Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands., van Erp NP; Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands.

Publikováno v: Molecular oncology [Mol Oncol] 2021 Sep; Vol. 15 (9), pp. 2453-2465. Date of Electronic Publication: 2021 May 29.